{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T16:07:49Z","timestamp":1785600469588,"version":"3.56.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016421","name":"Cardiovascular Medical Research and Education Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016421","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017463","name":"School of Dental Medicine, University of Pittsburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.chest.2019.10.043","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T19:57:34Z","timestamp":1573847854000},"page":"955-965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents"],"prefix":"10.1016","volume":"157","author":[{"given":"Vallerie V.","family":"McLaughlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Channick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"De Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison W.","family":"Farber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Gaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazzareno","family":"Gali\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Krasuski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Preston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogerio","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Gerry","family":"Coghlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Frantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hemnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Langleben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Sitbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Tapson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adaani","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.chest.2019.10.043_bib1","doi-asserted-by":"crossref","first-page":"1801889","DOI":"10.1183\/13993003.01889-2018","article-title":"Risk stratification and medical therapy of pulmonary arterial hypertension","volume":"53","author":"Gali\u00e8","year":"2019","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2019.10.043_bib2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.chest.2018.11.030","article-title":"Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel\u00a0report","volume":"155","author":"Klinger","year":"2019","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2019.10.043_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.chest.2019.10.043_bib4","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","article-title":"Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension","volume":"40","author":"Simonneau","year":"2012","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2019.10.043_bib5","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2019.10.043_bib6","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.chest.2019.10.043_bib7","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1378\/chest.12-2875","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial","volume":"144","author":"Tapson","year":"2013","journal-title":"Chest"},{"issue":"26","key":"10.1016\/j.chest.2019.10.043_bib8","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2019.10.043_bib9","series-title":"The RAND\/UCLA Appropriateness Method User's Manual","author":"Fitch","year":"2001"},{"issue":"3","key":"10.1016\/j.chest.2019.10.043_bib10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijcard.2008.11.051","article-title":"Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension","volume":"140","author":"Ghio","year":"2010","journal-title":"Int J Cardiol"},{"issue":"7","key":"10.1016\/j.chest.2019.10.043_bib11","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0735-1097(02)01744-8","article-title":"Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension","volume":"39","author":"Raymond","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.chest.2019.10.043_bib12","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1378\/chest.10-2015","article-title":"Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension","volume":"139","author":"Sachdev","year":"2011","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.chest.2019.10.043_bib13","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/eurheartj\/ehl477","article-title":"Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension","volume":"28","author":"van Wolferen","year":"2007","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.chest.2019.10.043_bib14","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1378\/chest.12-3023","article-title":"Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis","volume":"144","author":"Frost","year":"2013","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.chest.2019.10.043_bib15","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/art.39220","article-title":"Adverse events in connective tissue disease-associated pulmonary arterial hypertension","volume":"67","author":"Rhee","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.chest.2019.10.043_bib16","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1378\/chest.12-0653","article-title":"Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era","volume":"144","author":"Rubenfire","year":"2013","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2019.10.043_bib17","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1378\/chest.13-3014","article-title":"Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry","volume":"146","author":"Chung","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.chest.2019.10.043_bib18","unstructured":"National Institutes of Health Clinical Center. Phase III clinical worsening study of UT-15C in subjects with PAH receiving background oral monotherapy (FREEDOM-EV). NCT01560624. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2012. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01560624. Updated May 7, 2019."},{"issue":"7","key":"10.1016\/j.chest.2019.10.043_bib19","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0025-6196(11)60747-7","article-title":"Wide variation in clinicians' assessment of New York Heart Association\/World Health Organization functional class in patients with pulmonary arterial hypertension","volume":"84","author":"Taichman","year":"2009","journal-title":"Mayo Clin Proc"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236921934214X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236921934214X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T22:58:44Z","timestamp":1762124324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001236921934214X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S001236921934214X"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2019.10.043","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2019.10.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}